Samuel Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samuel Castro has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Candice R. Gurbatri
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
2 shared publications Ioana Lia
Columbia University, New York, NY
2 shared publications- Nicholas Arpaia
Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA
2 shared publications - Rosa L. Vincent
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
2 shared publications - Tal Danino
Department of Biomedical Engineering, Columbia University, New York, NY, USA
2 shared publications A Evans
23Department of Interventional Neuroradiology, University of Virginia School of Medicine, Charlottesville, VA, USA
1 shared publication
Latest Publications
- 19 December 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (3) , 521-524
Patient-defined Outcomes in Cardiovascular Surgery and Interventions
As cardiovascular patients live longer and undergo increasingly complex procedures, relying solely on mortality as benchmark of success is no longer sufficient. While patient-reported outcomes incorporate quality of life, symptoms, and functional status, they are often clinician-framed, lengthy, and difficult to integrate into routine care. Patient-defined outcomes is a patient-led evolution of this concept that emphasizes priorities such as autonomy and independence and avoiding outcomes deemed so undesirable that patients would sacrifice longevity to prevent them. Disability-free survival and patient-defined adverse cardiovascular and noncardiovascular events are composite patient-defined outcomes codeveloped with patients. Unlike patient-reported outcomes, which can be unwieldy, patient-defined outcomes are interpretable, autonomy-centered endpoints that extend beyond survival and traditional quality-of-life questionnaires. Integrating these measures into cardiac surgical and interventional workflows, especially during preoperative assessment and tailored optimization, helps align care with patient goals. Patient-defined outcomes have the potential to transform perioperative care by shifting the focus from living longer to living better.
- 19 December 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (3) , 521-524
Patient-defined Outcomes in Cardiovascular Surgery and Interventions
As cardiovascular patients live longer and undergo increasingly complex procedures, relying solely on mortality as benchmark of success is no longer sufficient. While patient-reported outcomes incorporate quality of life, symptoms, and functional status, they are often clinician-framed, lengthy, and difficult to integrate into routine care. Patient-defined outcomes is a patient-led evolution of this concept that emphasizes priorities such as autonomy and independence and avoiding outcomes deemed so undesirable that patients would sacrifice longevity to prevent them. Disability-free survival and patient-defined adverse cardiovascular and noncardiovascular events are composite patient-defined outcomes codeveloped with patients. Unlike patient-reported outcomes, which can be unwieldy, patient-defined outcomes are interpretable, autonomy-centered endpoints that extend beyond survival and traditional quality-of-life questionnaires. Integrating these measures into cardiac surgical and interventional workflows, especially during preoperative assessment and tailored optimization, helps align care with patient goals. Patient-defined outcomes have the potential to transform perioperative care by shifting the focus from living longer to living better.
- 18 September 2025
- Published by Wiley in Pediatric Anesthesia
- Vol. 35 (12) , 1080-1090
Augmented Reality Medical Simulation: A Multi‐Site Study of Factors That Influence Acceptance
Background: The infrequent occurrence of resuscitating critically ill pediatric patients poses educational challenges for pediatric anesthesiology residents developing competence. Traditional medical simulations, despite their utility, incur significant costs due to the need for monitors, mannequins, and personnel. Augmented reality (AR) medical simulation shows promise as an alternative clinical teaching tool. The Technology Acceptance Model (TAM) assesses usefulness, ease of use, and attitudes toward new technologies, offering insights into their adoption. Following successful application with other healthcare innovations, the TAM can also assess innovations in pediatric anesthesiology resident education, including AR medical simulation. Aims: The primary aim identified factors that influenced acceptance of AR for medical simulation in pediatric anesthesiology using a TAM. The secondary aims assessed the model's reliability, usability, and ergonomics. Methods: This prospective, multi‐site study was carried out across nine academic children's hospitals around the United States and Hong Kong. We recruited anesthesiology residents with a minimum of two weeks of pediatric anesthesia experience, excluding those with severe motion sickness, seizures, or who wore corrective glasses. Using Magic Leap 1 headsets, participants underwent a simulated AR pediatric resuscitation scenario. Data were collected via electronic surveys, evaluating TAM factors, usability (System Usability Scale), and ergonomics (ISO 9241‐400 standard). Results: A total of 101 participants completed the study. The AR TAM model indicated that perceived ease of use and computer self‐efficacy predicted perceived usefulness. Behavioral intention to use the AR system was influenced by perceived usefulness and perceived ease of use. System usability scores showed 83% agreement on ease of use. Ergonomic assessments indicated minimal physical discomfort. Conclusion: AR simulations are highly acceptable and usable for pediatric resuscitation training, with perceived ease of use and computer self‐efficacy influencing AR adoption. These findings align with previous TAM studies, supporting AR's potential to supplement traditional simulations and enhance accessibility.
- 18 September 2025
- Published by Wiley in Pediatric Anesthesia
- Vol. 35 (12) , 1080-1090
Augmented Reality Medical Simulation: A Multi‐Site Study of Factors That Influence Acceptance
Background: The infrequent occurrence of resuscitating critically ill pediatric patients poses educational challenges for pediatric anesthesiology residents developing competence. Traditional medical simulations, despite their utility, incur significant costs due to the need for monitors, mannequins, and personnel. Augmented reality (AR) medical simulation shows promise as an alternative clinical teaching tool. The Technology Acceptance Model (TAM) assesses usefulness, ease of use, and attitudes toward new technologies, offering insights into their adoption. Following successful application with other healthcare innovations, the TAM can also assess innovations in pediatric anesthesiology resident education, including AR medical simulation. Aims: The primary aim identified factors that influenced acceptance of AR for medical simulation in pediatric anesthesiology using a TAM. The secondary aims assessed the model's reliability, usability, and ergonomics. Methods: This prospective, multi‐site study was carried out across nine academic children's hospitals around the United States and Hong Kong. We recruited anesthesiology residents with a minimum of two weeks of pediatric anesthesia experience, excluding those with severe motion sickness, seizures, or who wore corrective glasses. Using Magic Leap 1 headsets, participants underwent a simulated AR pediatric resuscitation scenario. Data were collected via electronic surveys, evaluating TAM factors, usability (System Usability Scale), and ergonomics (ISO 9241‐400 standard). Results: A total of 101 participants completed the study. The AR TAM model indicated that perceived ease of use and computer self‐efficacy predicted perceived usefulness. Behavioral intention to use the AR system was influenced by perceived usefulness and perceived ease of use. System usability scores showed 83% agreement on ease of use. Ergonomic assessments indicated minimal physical discomfort. Conclusion: AR simulations are highly acceptable and usable for pediatric resuscitation training, with perceived ease of use and computer self‐efficacy influencing AR adoption. These findings align with previous TAM studies, supporting AR's potential to supplement traditional simulations and enhance accessibility.
- 1 September 2025
- Published by Oxford University Press (OUP) in Academic Medicine
Language as Healing: The Moment I Understood My Place in Medicine
- 1 September 2025
- Published by Oxford University Press (OUP) in Academic Medicine
Language as Healing: The Moment I Understood My Place in Medicine
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A114.1-A114
E-065 Interim safety and occlusion outcomes of endovascular treatment of large intracranial aneurysms in the sterling registry
Introduction Endovascular treatment for intracranial aneurysms has been evolving. Since the results of the ISAT and BRAT trial were published, multiple advancement of endovascular devices and procedures have occurred. The aim of this study is to share interim results for large aneurysms (> 10 mm) treated within the STERLING registry. Methods The STERLING registry (NCT03642639) is a Prospective, Multi-center, Single Arm Study to Obtain ’Real World’ Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms (Cerenovus, Irvine, CA). The primary endpoint was adequate occlusion rate without retreatment at 12 months measured by Independent Core Lab. Secondary outcome measures were packing density, good functional outcome (mRS 0-2), as well as device-related serious events and retreatment rate within 1-year. Results Among the 450 subjects in the STERLING interim analysis, 44 patients had large aneurysms. Mean (Standard Deviation [SD]) age was 60.6(11.35), and most patients were females (77.3%). Hypertension was prevalent in (59.1%) of the cohort, while half of the cohort were smokers and (13.6%) had a history of SAH. Baseline mRS score was 0 and 1 in 61.4% and 27.3%, respectively. Mean (SD) aneurysm height and width were 11.06 mm (3.78) and 10.67 mm (3.44), respectively. Most aneurysms were in the anterior circulation (84.1%) and (61.9%) were sidewall. Median (IQR) dome to neck ratio was 2.0 (1.70-2.65) and 35 (79.5%) aneurysms had a wide neck. Saccular aneurysm was the most common morphology (86.4%) and (27.3%) were ruptured aneurysms. Most common method of treatment was primary coiling (n=16) followed by coiling+flow diversion (n=12). Mean (SD) packing density was 16.8(8.88). Adequate occlusion on 1-year follow-up was achieved in 86.7% (13/15) and four patients required retreatment within 1-year, resulting in 66.7% (10/15) patients with adequate occlusion without retreatment. There was no occurrence of intraprocedural rupture nor symptomatic intraprocedural thromboembolic events. Clinical outcome was available for unruptured aneurysms for 1 year follow-up and good functional outcome was achieved in 85.7% (12/14). Device related significant adverse events occurred in 1 patient only (2.3%). Conclusion Early results from the STERLING registry for large aneurysms are promising. Adequate occlusion per Independent Core Lab was achieved in 86.7% and retreatment rates were relatively low over 1-year follow-up. A good functional outcome was achieved in 85.7% of patients Disclosures O. Zaidat: 1; C; Stryker, Medtronic, Cerenovus, Penumbra, and Genentech. 2; C; Stryker, Medtronic, Cerenovus, Penumbra, and Neuravi. 4; C; ownership interest in Galaxy Therapeutics LLC;. 6; C; honoraria from Codman,Stryker,Penumbra, Medtronic. serves on the endovascular committee as co-chair for NIH StrokeNet Consortium; has served as an expert witness; had a patent for Ischemic stroke.. Y. Ashouri: None. R. Starke: 2; C; Medtronic Neurovascular, Penumbra, Cerenovus, Abbott.,. A. Puri: 1; C; Stryker Neurovascular, Medtronic, Cerenovus. He has received NIH grants. 2; C; tryker Neurovascular, Medtronic, Cerenovus, Microvention, QApel, Perfuze Medical, Arsenal Medical, Merit Medical Agile, Corindus, Imperative Care. 4; C; InNeuroCo Inc, Galaxy therapeutics, Agile Medical, Perfuze medical and Neurotechnology Investors. B. Jankowitz: None. A. Yoo: 1; C; Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. 2; C; Cerenovus, Penumbra, and Zoll. 6; C; Equity interest in Insera Therapeutics. G. Marnat: None. Z. Kulcsar: None. K. Sugiu: None. S. Jahshan: None. P. Machi: None. G. Pero: None. S. Castro: None. J. Howington,: None. C. Schirmer: None. C. Kilburg: None. C. Chivot: None. F. Al-Mufti: None. V. Da Ros: None. B. Gory: None. T. Yao: 2; C; Medtronic. A. Polifka: None. O. Francois,: None. A. Evans: None. J. Machaj: None. R. De Leacy: 2; C; Imperative Care, Cerenovus, Siemens Healthineers, Penumbra. 6; C; equity in Synchron, Endostream, Q’Apel Medical, Spartan Micro, Vastrax.
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A114.1-A114
Open AccessE-065 Interim safety and occlusion outcomes of endovascular treatment of large intracranial aneurysms in the sterling registry
Introduction Endovascular treatment for intracranial aneurysms has been evolving. Since the results of the ISAT and BRAT trial were published, multiple advancement of endovascular devices and procedures have occurred. The aim of this study is to share interim results for large aneurysms (> 10 mm) treated within the STERLING registry. Methods The STERLING registry (NCT03642639) is a Prospective, Multi-center, Single Arm Study to Obtain ’Real World’ Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms (Cerenovus, Irvine, CA). The primary endpoint was adequate occlusion rate without retreatment at 12 months measured by Independent Core Lab. Secondary outcome measures were packing density, good functional outcome (mRS 0-2), as well as device-related serious events and retreatment rate within 1-year. Results Among the 450 subjects in the STERLING interim analysis, 44 patients had large aneurysms. Mean (Standard Deviation [SD]) age was 60.6(11.35), and most patients were females (77.3%). Hypertension was prevalent in (59.1%) of the cohort, while half of the cohort were smokers and (13.6%) had a history of SAH. Baseline mRS score was 0 and 1 in 61.4% and 27.3%, respectively. Mean (SD) aneurysm height and width were 11.06 mm (3.78) and 10.67 mm (3.44), respectively. Most aneurysms were in the anterior circulation (84.1%) and (61.9%) were sidewall. Median (IQR) dome to neck ratio was 2.0 (1.70-2.65) and 35 (79.5%) aneurysms had a wide neck. Saccular aneurysm was the most common morphology (86.4%) and (27.3%) were ruptured aneurysms. Most common method of treatment was primary coiling (n=16) followed by coiling+flow diversion (n=12). Mean (SD) packing density was 16.8(8.88). Adequate occlusion on 1-year follow-up was achieved in 86.7% (13/15) and four patients required retreatment within 1-year, resulting in 66.7% (10/15) patients with adequate occlusion without retreatment. There was no occurrence of intraprocedural rupture nor symptomatic intraprocedural thromboembolic events. Clinical outcome was available for unruptured aneurysms for 1 year follow-up and good functional outcome was achieved in 85.7% (12/14). Device related significant adverse events occurred in 1 patient only (2.3%). Conclusion Early results from the STERLING registry for large aneurysms are promising. Adequate occlusion per Independent Core Lab was achieved in 86.7% and retreatment rates were relatively low over 1-year follow-up. A good functional outcome was achieved in 85.7% of patients Disclosures O. Zaidat: 1; C; Stryker, Medtronic, Cerenovus, Penumbra, and Genentech. 2; C; Stryker, Medtronic, Cerenovus, Penumbra, and Neuravi. 4; C; ownership interest in Galaxy Therapeutics LLC;. 6; C; honoraria from Codman,Stryker,Penumbra, Medtronic. serves on the endovascular committee as co-chair for NIH StrokeNet Consortium; has served as an expert witness; had a patent for Ischemic stroke.. Y. Ashouri: None. R. Starke: 2; C; Medtronic Neurovascular, Penumbra, Cerenovus, Abbott.,. A. Puri: 1; C; Stryker Neurovascular, Medtronic, Cerenovus. He has received NIH grants. 2; C; tryker Neurovascular, Medtronic, Cerenovus, Microvention, QApel, Perfuze Medical, Arsenal Medical, Merit Medical Agile, Corindus, Imperative Care. 4; C; InNeuroCo Inc, Galaxy therapeutics, Agile Medical, Perfuze medical and Neurotechnology Investors. B. Jankowitz: None. A. Yoo: 1; C; Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. 2; C; Cerenovus, Penumbra, and Zoll. 6; C; Equity interest in Insera Therapeutics. G. Marnat: None. Z. Kulcsar: None. K. Sugiu: None. S. Jahshan: None. P. Machi: None. G. Pero: None. S. Castro: None. J. Howington,: None. C. Schirmer: None. C. Kilburg: None. C. Chivot: None. F. Al-Mufti: None. V. Da Ros: None. B. Gory: None. T. Yao: 2; C; Medtronic. A. Polifka: None. O. Francois,: None. A. Evans: None. J. Machaj: None. R. De Leacy: 2; C; Imperative Care, Cerenovus, Siemens Healthineers, Penumbra. 6; C; equity in Synchron, Endostream, Q’Apel Medical, Spartan Micro, Vastrax.
- 15 August 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (16_Supplem) , 6248
Abstract 6248: Engineered probiotics for local delivery of checkpoint blockade nanobodies
Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of patients and can lead to a multitude of toxicities, suggesting the need for more targeted delivery systems. Because of their preferential colonization of tumors, microbes are a natural platform for the local delivery of cancer therapeutics. Here, we engineer a probiotic bacteria system for the controlled production and intratumoral release of nanobodies targeting programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) using a stabilized lysing release mechanism. We used computational modeling coupled with experimental validation of lysis circuit dynamics to determine the optimal genetic circuit parameters for maximal therapeutic efficacy. A single injection of this engineered system demonstrated an enhanced therapeutic response compared to analogous clinically relevant antibodies, resulting in tumor regression in syngeneic mouse models. Supporting the potentiation of a systemic immune response, we observed a relative increase in activated T cells, an abscopal effect, and corresponding increases in systemic T cell memory populations in mice treated with probiotically delivered checkpoint inhibitors. Last, we leveraged the modularity of our platform to achieve enhanced therapeutic efficacy in a poorly immunogenic syngeneic mouse model through effective combinations with a probiotically produced cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). Together, these results demonstrate that our engineered probiotic system bridges synthetic biology and immunology to improve upon checkpoint blockade delivery. Citation Format: Candice Gurbatri, Ioana Lia, Rosa Vincent, Courtney Coker, Samuel Castro, Piper Treuting, Taylor Hinchliffe, Nicholas Arpaia, Tal Danino. Engineered probiotics for local delivery of checkpoint blockade nanobodies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6248.
- 15 August 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (16_Supplem) , 6248
Abstract 6248: Engineered probiotics for local delivery of checkpoint blockade nanobodies
Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of patients and can lead to a multitude of toxicities, suggesting the need for more targeted delivery systems. Because of their preferential colonization of tumors, microbes are a natural platform for the local delivery of cancer therapeutics. Here, we engineer a probiotic bacteria system for the controlled production and intratumoral release of nanobodies targeting programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) using a stabilized lysing release mechanism. We used computational modeling coupled with experimental validation of lysis circuit dynamics to determine the optimal genetic circuit parameters for maximal therapeutic efficacy. A single injection of this engineered system demonstrated an enhanced therapeutic response compared to analogous clinically relevant antibodies, resulting in tumor regression in syngeneic mouse models. Supporting the potentiation of a systemic immune response, we observed a relative increase in activated T cells, an abscopal effect, and corresponding increases in systemic T cell memory populations in mice treated with probiotically delivered checkpoint inhibitors. Last, we leveraged the modularity of our platform to achieve enhanced therapeutic efficacy in a poorly immunogenic syngeneic mouse model through effective combinations with a probiotically produced cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). Together, these results demonstrate that our engineered probiotic system bridges synthetic biology and immunology to improve upon checkpoint blockade delivery. Citation Format: Candice Gurbatri, Ioana Lia, Rosa Vincent, Courtney Coker, Samuel Castro, Piper Treuting, Taylor Hinchliffe, Nicholas Arpaia, Tal Danino. Engineered probiotics for local delivery of checkpoint blockade nanobodies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6248.
- Top Cited Papers
- 12 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (530)
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
An engineered probiotic system locally delivers checkpoint blockade nanobodies to tumors for sustained therapeutic release.
- 12 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (530)
Top Cited PapersEngineered probiotics for local tumor delivery of checkpoint blockade nanobodies
An engineered probiotic system locally delivers checkpoint blockade nanobodies to tumors for sustained therapeutic release.